SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, has released a limited edition holiday ornament that will support its mission to find and provide treatments for nano-rare patients (30 or fewer patients worldwide affected by a single gene mutation). Unveiled in advance of Giving Tuesday, the one-of-a-kind “I Heart Nano-rare” flat, shatterproof ornament will be sent to anyone who donates at least $25 to the organization. Donations to n-Lorem support the 100 patients already accepted for potential personalized treatments for free, for life and future patients. Already n-Lorem has filed nine investigational new drug (IND) applications with the FDA, begun treatment on five patients and plans to begin treatment on additional patients before the end of the year.
“Though we are celebrating our successes, there is a lot more to do,” said Stanley T. Crooke, M.D., Ph.D., Founder, Chairman and CEO, n-Lorem Foundation. “This is about a dream that was impossible. Everyone said it was impossible until we showed them what we could do. We are providing hope to the hopeless. Creating futures where futures didn’t previously exist. But we can’t do this alone. We need help to develop therapies and every donation we receive helps those in need.”
The ornament can be mailed anywhere in the U.S., and people who are purchasing the ornament as a gift can include a personalized message with it. Anyone who wants to order the ornament can find it here: https://www.nlorem.org/holiday-ornament-2023/
To read the USA Today article that follows two n-Lorem patient stories, the story is available online or in the hard copy of the Monday, Nov. 27, 2023 edition.
About n-Lorem
n-Lorem Foundation is a nonprofit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem received over 225 applications for treatment with approximately 100 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on Twitter, Facebook, LinkedIn and YouTube.
Learn more about n-Lorem’s mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these patients and families in need.
